Insider Buy: Precigen
5:06PM ET 11/30/2021 MT NewswiresHarry Thomasian Jr., Chief Financial Officer, on November 26, 2021, executed a purchase for 26,500 shares in Precigen (PGEN) for $100,831. Following the...
Quotes Snapshot > PGEN
Precigen Inc PGEN:NASDAQ
Last Price$2.81NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/21/22
NASDAQ 15-minute delayed Bid/Ask Quotes
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$2.78 (20)
Ask (Size)$2.80 (26)
Day Low / HighN/A - N/A
Volume1.8 M
Read more news Recent News
Insider Buy: Precigen
6:00AM ET 11/24/2021 MT NewswiresRandal J Kirk, 10% Owner, Director, on November 19, 2021, executed a purchase for 1,000,000 shares in Precigen (PGEN) for $3,634,787. Following the Form 4...
Precigen Gets FDA Nod to Begin Early-Stage PRGN-3007 Trial in Hematological, Solid Tumors
1:54PM ET 10/26/2021 MT NewswiresPrecigen (PGEN) said Tuesday that the US Food and Drug Administration has approved its investigational new drug application to initiate the phase 1/1b test...
Precigen Appoints CFO
10:16AM ET 10/12/2021 MT NewswiresPrecigen (PGEN) said Tuesday that Harry Thomasian Jr. was named as its new CFO effective Oct. 18. Thomasian served most recently as senior client services...
View all Commentary and Analysis
Pipeline and Corporate Updates at 40th Annual JP Morgan Health Care Conference (SlideShow)
10:43PM ET 1/12/2022 Seeking AlphaPrecigen (PGEN) Investor Presentation - Slideshow
2:36PM ET 1/12/2022 Seeking AlphaPrecigen: A Substantially Undervalued And Differentiated Gene Therapy Company
8:00AM ET 1/10/2022 Seeking AlphaThe Prognosis On Precigen
12:58PM ET 1/05/2022 Seeking AlphaCompany Profile
Business DescriptionPrecigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD. View company web site for more details
| Address | 20374 Seneca Meadows Parkway Germantown, Maryland 20876 |
| Phone | +1.301.556.9900 |
| Number of Employees | 882 |
| Recent SEC Filing | 01/06/2022 4 |
| President, Chief Executive Officer & Director | Helen Sabzevari |
| Head-Operations & Portfolio | Rutul R. Shah |
| Chief Financial Officer | Harry Thomasian |
| Chief Science Officer | Thomas David Reed |
Company Highlights
| Price Open | $3.00 |
| Previous Close | $2.96 |
| 52 Week Range | $2.80 - 9.89 |
| Market Capitalization | $580.9 M |
| Shares Outstanding | 206.7 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 03/07/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$0.66 |
| Beta vs. S&P 500 | N/A |
| Revenue | $160.6 M |
| Net Profit Margin | -73.45% |
| Return on Equity | -54.62% |
Analyst Ratings as of 02/24/2021
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |